US FDA eliminates outdated UV filters as regulatory modernization continues

The US Food and Drug Administration (FDA) is removing aminobenzoic acid (PABA) and trolamine salicylate from its over-the-counter (OTC) sunscreen monograph. The move follows the FDA’s recent addition of bemotrizinol (BEMT) as a permitted sunscreen active ingredient and forms part of a broader modernization of the US sunscreen regulatory framework.

EU Launches New Agri-Food Innovation Strategy to Future-Proof Agriculture and Food Systems

By Editor, Global AgInvesting Media The European Commission has officially adopted a comprehensive new Strategic Approac…

Symrise completes Floral Concept acquisition to strengthen premium naturals portfolio

Symrise has completed its acquisition of Floral Concept, acquiring 100% share capital and integrating the French premium natural fragrance ingredients house into its Fragrance division. The acquisition boosts Symrise’s competitiveness in the natural fine fragrance space as demand grows for differentiated, traceable, and sustainably sourced natural ingredients in perfumery.

Molecular Devices and STEMCELL Technologies Team Up to Automate Organoid Research

Molecular Devices and STEMCELL Technologies said they have a developed a validated automated workflow that can be used with STEMCELL’s IntestiCult™ Plus organoid growth medium for human intestinal organoids culture on the Molecular Devices CellXpress.ai automated cell culture system.

How Planted is Outpacing Competitors in Europe’s Largest Plant-Based Meat Market

Planted, one of Europe’s leading meat alternative makers, is outperforming the sector in Europe’s leading meat alternative market.

Novartis pays $125M for Sironax brain delivery platform

Why it matters: The deal is part of a broader Novartis push to solve one of neurology’s biggest technical problems: getting large therapeutic molecules across the blood-brain barrier. Rather than betting on a single approach, the Swiss pharma is assembling several brain-shuttle technologies that could work with different drug classes.

Orbis lands $1.4B macrocycle partnership with Novo

Why it matters: The deal is another big pharma endorsement of macrocycles as a way to combine some of the target-binding properties of biologics with the convenience of oral drugs. It also gives Orbis its first Big Pharma partnership, less than two years after the company emerged from stealth.

Roche taps Dualitas in $1B bispecific deal

Why it matters: Bispecific antibodies, long concentrated in oncology, are increasingly moving into autoimmune and inflammatory diseases. Roche is already developing several approaches in the field, and the Dualitas deal gives it a way to search much more broadly for new target combinations.

High-Grade Glioma Biology Varies by Age and Sex, Revealing Potential Treatment Targets

Researchers at the Icahn School of Medicine at Mount Sinai and collaborators have identified candidate treatment targets and potential prognostic markers for high-grade glioma (HGG), an aggressive brain cancer in children, adolescents, and young adults (AYA). The study found that high-grade glioma varies by developmental stage and sex, showing distinct tumor biology and outcomes across patient groups.

AgriFood Signals: Syngenta HK IPO, Terradot and Google do enhanced rock weathering, Corteva split lawsuits

AgFunderNews rounds up the most important fundings, mergers, acquisitions, closures, and industry buzz in agtech and foo…